PPT1 and Hypoglycemia: Additional autophagy-modulating agents have been described, such as the repurposed antimalarial compound chloroquine (CQ) and its less toxic derivative hydroxychloroquine (HCQ), which impair lysosomal acidification by targeting palmitoyl-protein thioesterase 1 (PPT1), but these compounds have severe side effects by interfering with human ether-à-go-go-related gene (hERG) responsible for electrical activity of the heart17,18 and they can also cause gastrointestinal side effects, impact visual and auditory function, and lead to hypoglycemia.